These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32110522)

  • 1. Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study.
    Ahmadi J; Sarani EM; Jahromi MS
    Ci Ji Yi Xue Za Zhi; 2020; 32(1):58-64. PubMed ID: 32110522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
    Ahmadi J; Jahromi MS; Ehsaei Z
    Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single high-dose buprenorphine for opioid craving during withdrawal.
    Ahmadi J; Jahromi MS; Ghahremani D; London ED
    Trials; 2018 Dec; 19(1):675. PubMed ID: 30526648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-Low-Dose Buprenorphine as a Time-Limited Treatment for Severe Suicidal Ideation: A Randomized Controlled Trial.
    Yovell Y; Bar G; Mashiah M; Baruch Y; Briskman I; Asherov J; Lotan A; Rigbi A; Panksepp J
    Am J Psychiatry; 2016 May; 173(5):491-8. PubMed ID: 26684923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Haight BR; Learned SM; Laffont CM; Fudala PJ; Zhao Y; Garofalo AS; Greenwald MK; Nadipelli VR; Ling W; Heidbreder C;
    Lancet; 2019 Feb; 393(10173):778-790. PubMed ID: 30792007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of opioid dependence with buprenorphine/naloxone sublingual tablets: A phase 3 randomized, double-blind, placebo-controlled trial.
    Wang X; Jiang H; Zhao M; Li J; Gray F; Sheng L; Li Y; Li X; Ling W; Li W; Hao W
    Asia Pac Psychiatry; 2019 Mar; 11(1):e12344. PubMed ID: 30460781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving.
    Ahmadi J; Sahraian A; Biuseh M
    Trials; 2019 Jul; 20(1):468. PubMed ID: 31362784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
    Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
    JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the effect of buprenorphine and methadone in the reduction of methamphetamine craving: a randomized clinical trial.
    Ahmadi J; Razeghian Jahromi L
    Trials; 2017 Jun; 18(1):259. PubMed ID: 28587620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suicidal ideation is associated with individual differences in prescription opioid craving and cue-reactivity among chronic pain patients.
    Garland EL; Riquino MR; Priddy SE; Bryan CJ
    J Addict Dis; 2017; 36(1):23-29. PubMed ID: 27644963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.
    Kowalczyk WJ; Phillips KA; Jobes ML; Kennedy AP; Ghitza UE; Agage DA; Schmittner JP; Epstein DH; Preston KL
    Am J Psychiatry; 2015 Aug; 172(8):760-7. PubMed ID: 25783757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine implants for treatment of opioid dependence: randomized comparison to placebo and sublingual buprenorphine/naloxone.
    Rosenthal RN; Ling W; Casadonte P; Vocci F; Bailey GL; Kampman K; Patkar A; Chavoustie S; Blasey C; Sigmon S; Beebe KL
    Addiction; 2013 Dec; 108(12):2141-9. PubMed ID: 23919595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anxiety Treatment of Opioid Dependent Patients with Buprenorphine: A Randomized, Double-blind, Clinical Trial.
    Ahmadi J; Jahromi MS
    Indian J Psychol Med; 2017; 39(4):445-449. PubMed ID: 28852238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naïve to potent opioids.
    Breivik H; Ljosaa TM; Stengaard-Pedersen K; Persson J; Aro H; Villumsen J; Tvinnemose D
    Scand J Pain; 2010 Jul; 1(3):122-141. PubMed ID: 29913983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
    Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
    Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.